Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
- Status
- COMPLETED
- Phase
- PHASE3
Trial of pIL-12/MK-3475 in Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- NA
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
- Status
- COMPLETED
- Phase
- PHASE2
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
- Status
- COMPLETED
- Phase
- PHASE1